Funicular Funds Supports for Strategic Review at Synlogic, Inc (SYBX)

Key Summary: Funicular Funds applauds the Board's prompt response. They aim to contribute to the strategic review process.

Market Cap: $17 million| Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic and immunological diseases in the United States.

On February 16, 2024, Funicular Funds (36%) extends condolences for a clinical setback and applauds the Board's prompt response. They aim to contribute to the strategic review process. Source